Page 10 - Optune Lua News Today

Equities research analysts at HC Wainwright started coverage on shares of NovoCure (NASDAQ:NVCR – Get Rating) in a research note issued to investors on Monday, The Fly reports. The brokerage set a “buy” rating on the medical equipment provider’s stock. NVCR has been the topic of several other research reports. Truist Financial upgraded shares of […]

Company to Host Conference Call and Webcast on May 11, 2022, at 8:00 a.m. ET...

NovoCure (NASDAQ:NVCR – Get Rating) is scheduled to be announcing its earnings results before the market opens on Thursday, April 28th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link. NovoCure (NASDAQ:NVCR – Get Rating) […]

Brokerages expect that NovoCure Limited (NASDAQ:NVCR – Get Rating) will announce earnings of ($0.17) per share for the current quarter, Zacks reports. Five analysts have made estimates for NovoCure’s earnings, with the lowest EPS estimate coming in at ($0.22) and the highest estimate coming in at ($0.11). NovoCure posted earnings of ($0.04) per share in […]

NovoCure Limited (NASDAQ:NVCR – Get Rating) has earned a consensus recommendation of “Hold” from the eleven analysts that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, three have given a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective […]

NovoCure (NASDAQ:NVCR – Get Rating) and Alphatec (NASDAQ:ATEC – Get Rating) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, earnings, profitability and institutional ownership. Institutional & Insider Ownership 74.5% of NovoCure shares are owned by institutional […]

Gulf International Bank UK Ltd trimmed its stake in NovoCure Limited (NASDAQ:NVCR – Get Rating) by 19.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,842 shares of the medical equipment provider’s stock after selling 4,000 shares during the quarter. […]

NovoCure stock is way down and attracting bargain shoppers.

Quarterly net revenues of $133.6 million with 77% gross margin Last patient enrolled in phase 3 pivotal INNOVATE-3 trial for recurrent ovarian cancer Novocure (NASDAQ: NVCR) today reported financial

Novocure Reports First Quarter 2021 Financial Results and Provides Company Update Quarterly net revenues of $134.7 million with 80% gross margin Interim analysis for phase 3 pivotal LUNAR trial in non-small cell lung cancer concluded with favorable recommendation to continue the trial with reduced sample size Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2021, highlighting continued commercial strength despite changes in patterns of care in some region...